The range of inactivity was the lowest for the nuclear androgen receptor-ligand-binding domain (NR-AR-LBD), with values of approximately 50%, and the highest for the nuclear androgen receptor (NR-AR), a crucial transcriptional regulator and therapeutic target in prostate cancer, with values of approximately 100%. Here, AR is linked to prostate carcinoma.